Multispecific Antibodies

IMUNEXIN^TM MULTISPECIFIC ANTIBODIES: WHAT ARE THEY?

A normal monoclonal antibody can bind to one specific therapeutic target (i.e. it has one specificity). Our multispecifics are engineered proteins that are composed of imunexins^TM genetically fused to a parent antibody. imunexins^TM can be fused to the constant heavy and/or to the constant light regions of an antibody. One pair of imunexins^TM fused to an antibody generates a bispecific (i.e. it has two specificities) while two pairs of imunexins^TM with different binding specificities fused to an antibody generate a trispecific (i.e. it has three specificities).

Diagram showing a monospecific antibody converted into a bispecific antibody by genetically fusing imunexins^TM
to the antibody constant region (elements not drawn to scale)

Diagram showing a monospecific antibody converted into a trispecific antibody by genetically fusing imunexins^TM
to the antibody constant regions (elements not drawn to scale)

POTENTIAL APPLICATIONS FOR MULTISPECIFIC ANTIBODIES:

Multispecific antibodies have the potential to become important therapeutics for a number of diseases. Some of the potential applications for multispecifics are outlined:

• Redirect and activate immune effector cells to specifically kill tumours.
• Bind to multiple targets and effect multiple pathogenic pathways.
• Bind to multiple sites on the one target cell or protein to increase specificity or induce synergistic induction.
• Target tumours that are heterogeneous.
• Increase the half-life of whole antibodies, antibody fragments, or other proteins.
• Bind to transport proteins to allow antibodies to cross biological barriers.